This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. JDQ443 (Novartis Institute for Biomedical Research) is an oral KRASG12C inhibitor being developed for various advanced solid tumors. Despite…
molecule
1 year ago ●
6 mins read
Context. AZD4625 (AstraZeneca) is an oral inhibitor of KRASG12C being developed for the treatment of advanced solid malignancies. As indicated…
molecule
1 year ago ●
4 mins read
Context. JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR…
molecule
1 year ago ●
6 mins read
Context. ABBV-318 (AbbVie) is a CNS-penetrating, oral inhibitor of Nav1.7/Nav1.8 being developed for pain treatment. Despite being a highly validated…
molecule
1 year ago ●
4 mins read
Context. Tenapanor (Ardelyx) is an oral, first-in-class Na+/H+ exchanger isoform 3 (NHE3) inhibitor approved by the FDA for irritable bowel…
molecule
1 year ago ●
5 mins read
Context. Lenrispodun (Intra-Cellular Therapies) is a phosphodiesterase (PDE) type 1 (PDE1) inhibitor being developed for CNS and non-CNS disorders, including…
molecule
1 year ago ●
6 mins read
Load More
